Health News Archive - June 26, 2010
ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
ORLANDO, Fla., June 26 /PRNewswire/ -- Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose (PPG).(1,2) Boehringer Ingelheim Pharmaceuticals, Inc.
ORLANDO, Fla., June 26 /PRNewswire-FirstCall/ -- Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily VictozaÂ® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than JanuviaÂ® plus metformin at 52 weeks. Key findings from the study include: Patients treated with 1.2 mg and 1.8 mg of VictozaÂ® experienced greater reductions in A1c than those treated with JanuviaÂ® 100 mg (-1.3% and -1.5% versus -0.9%)VictozaÂ® provided greater weight loss versus patients treated with JanuviaÂ® (2.8 kg [6.16 lbs] and 3.7 kg [8.14 lbs] for 1.2 mg and 1.8 mg respectively, 1.2 kg [2.64 lbs] for JanuviaÂ®) VictozaÂ® provided greater change from baseline FPG readings than those treated with JanuviaÂ® (-1.7 mmol/L and -2.0 mmol/L for 1.2 mg and 1.8 mg respectively, versus -0.6 mmol/L)Patients
ORLANDO, Fla., June 26 /PRNewswire-FirstCall/ -- Studies of a more-rapid-acting injectable human insulin formulation (VIAjectÂ®) in the treatment of type 1 and type 2 diabetes and of a novel insulin analog formulation (Vialog(TM)) in an animal model of diabetes were reported this week in three poster presentations at the 70th Scientific Sessions of the American Diabetes Association in Orlando, Florida.
ORLANDO, Fla., June 26 /PRNewswire-FirstCall/ -- OrexigenÂ® Therapeutics, Inc.
PARIS, June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a study which demonstrated that patients using LantusÂ® (insulin glargine [rDNA origin] injection) once-daily and ApidraÂ® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin.
SAN ANTONIO, June 26 /PRNewswire/ -- Today, San Antonio-based NatureSweetÂ® in partnership with local organizations, Stroller Strides and SAMMinistries, kicked off the SunBursts Stroller Project, a two-part program to provide more than 25 families in need with new baby strollers and fun, stroller-based exercise classes.
ORLANDO, Fla., June 26 /PRNewswire/ -- An estimated 75 percent of adults with type 1 and type 2 diabetes say they believe they know what their blood sugar levels are without testing, according to data presented at the American Diabetes Association (ADA) 70th Scientific Sessions.
ORLANDO, Fla., June 26 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.